A Phase 4 interventional study of Anticoagulant Therapy in Percutaneous Coronary Intervention, High Bleeding Risk and Acute Coronary Syndromes, sponsored by Shenyang Northern Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Shenyang Northern Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital — 5 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Shenyang Northern Hospital.
Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, this one is one of 3 that started in 2026, is one of 8 in phase 4, and was the 12th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →5 of the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital are open now, in 1 country. Recruiting first, the newest first:
Shenyang Northern Hospital · Sites in China
Ages 18+
Shenyang Northern Hospital · Sites in China
Ages 18–80
Shenyang Northern Hospital · Sites in China
Ages 18+
Shenyang Northern Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,270 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 723 across the 8 interventional studies, 2,500 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shenyang Northern Hospital is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
2 of the studies in Acute Coronary Syndrome by Shenyang Northern Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06216821Shenyang Northern HospitalOPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time | 2026-12-31 |
| NCT07351643Shenyang Northern HospitalCCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.
Methods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.
Conclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.
Study design BRIGHT-HBR is an investigator-sponsored, prospective, multicenter, open-label, active-controlled randomized trial. A total of 5,270 patients with NSTE-ACS and stabilized recent STEMI who are at HBR and are undergoing PCI with radial artery access will be enrolled at 70 sites in China. Patients are randomized 1:1 to two arms: bivalirudin vs. UFH monotherapy, with GPI reserved for bailout use in each group. The trial is powered to demonstrate the superiority of bivalirudin compared with UFH in reducing the 30-day rate of net adverse clinical events (NACE), the composite of all-cause death, MI, stroke, urgent target-vessel revascularization, or bleeding according to the Bleeding Academic Research Consortium (BARC) types 2, 3 or 5 criteria.
Randomization and study treatment Before diagnostic angiography, eligible patients will be randomly assigned in a 1:1 ratio to procedural anticoagulation with bivalirudin or UFH monotherapy. Allocation to treatment will be provided by an interactive web response system in randomly permuted block sizes of 4 or 6, with stratification according to the participating center, which is incorporated within an electronic data capture system.
In the UFH monotherapy group, an intravenous UFH bolus of 70 U/kg will be administered. The ACT will be measured 5 minutes after the first administration, and if the ACT is \<250 seconds (Hemotec assay), an additional intravenous bolus of 1000 U UFH will be administered, to ensure the re-checked ACT is ≥250 seconds prior to PCI.
In the bivalirudin group, an intravenous bolus dose of bivalirudin 0.75 mg/kg will be administered, followed by an intravenous infusion of 1.75 mg/(kg·h). The infusion dose (but not the bolus) is adjusted for renal insufficiency. The estimated glomerular filtration rate (eGFR) will be calculated by the formula: 186 × (serum creatinine [mg/dL])-1.154 × (age)-0.203 × (0.742 if female). For patients with moderate renal impairment (eGFR 30-59 ml/(min·1.73m2), the intravenous infusion dose is unchanged; for patients with severe renal impairment (eGFR \<30 ml/(min·1.73m2), the intravenous infusion dose is reduced to 1.0 mg/(kg·h); for patients undergoing dialysis, the intravenous infusion dose is reduced to 0.25 mg/(kg·h). The ACT will be monitored 5 minutes after the first bivalirudin bolus administration, and if the ACT is \<250 seconds (Hemotec assay), an additional intravenous bolus of 0.3 mg/kg of bivalirudin will be administered to ensure the re-checked ACT is ≥250 seconds prior to PCI. The intravenous bivalirudin infusion is discontinued immediately after PCI.
The PCI procedure is performed using standard techniques. Radial artery access is strongly recommended. PCI is recommended for vessels with a visually assessed coronary artery diameter ≥2.5 mm with stenosis ≥70% or fractional flow reserve (FFR) \<0.80 or ulcerated plaques. Complete revascularization is recommended if it may be safely achieved. PCI of chronic total occlusions (CTO) that are well-collateralized and supply viable myocardium is recommended if, in the opinion of an experienced CTO operator, there is a high likelihood of PCI success without complications or excessive contrast use. Drug-eluting stents should be used absent contraindications. Declaration of the target vessels will be made before PCI. A planned staged procedure in patients with complex or multivessel disease may be completed within 45 days and will not be considered an endpoint event. The intent to stage must be declared and documented at the end of the first procedure. The anticoagulation regimen during the planned staged procedure must be identical with that of the initial procedure. Any unplanned treatment, or a planned reintervention after 45 days will be considered an endpoint event.
Routine administration of a GPI during the procedure is prohibited. The use of intravenous or intracoronary tirofiban (the most widely used GPI in China) is restricted to specific procedural complications, including target vessel slow flow or no-reflow, refractory thrombus, or other thrombotic complications during PCI that cannot otherwise be effectively treated. When indicated, intravenous tirofiban should be initiated with a bolus infusion of 10-25 μg/kg (administered over >5 minutes), followed by a continuous maintenance infusion of 0.15 μg/(kg·min) for up to 18 hours. For patients with an eGFR \<60 mL/min, the maintenance dose should be reduced to 0.075 μg/(kg·min). Alternatively, an intracoronary bolus dose of 500-750 μg may be used, with repeat injections permitted at intervals of 3-5 minutes. The cumulative intracoronary dose should not exceed 1500-2250 μg. Other procedural medications are provided per standard of care.
Prior to the procedure the patient should be treated with aspirin and a standard loading dose followed by a daily dose of either ticagrelor or clopidogrel (ticagrelor strongly preferred). Dual antiplatelet therapy should be continued post-PCI per local standard of care and societal guidelines. Other chronic medications are administered per local standard of care.
Follow-up Clinical follow-up will be scheduled at 1, 3, 6, and 12 months via telephone or clinic visit after randomization. Throughout the study period, patients will be monitored for the occurrence of the following clinical events: death, MI, stroke, any repeat revascularization, and any bleeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bivalirudin
Drug: Anticoagulant Therapy
Unfractionated heparin monotherapy
Drug: Anticoagulant Therapy
The optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS)
Net adverse clinical events (NACE) at 30 days
The composite of all-cause death, MI, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding
Time frame: 30 days post PCI
BARC types 2, 3 or 5 bleeding at 30 days
Time frame: 30 days post PCI
NACE at 12 months
Time frame: 1 year post PCI
Each individual component of NACE at 30 days and 12 months
Time frame: 30 days and 1 year post PCI
Major adverse cardiac and cerebral events (MACCE) at 30 days and 12 months
Composite of all-cause death, MI, stroke, or urgent target-vessel revascularization
Time frame: 30 days and 1 year post PCI
BARC types 1, 2, 3, or 5 bleeding at 30 days and 12 months
Time frame: 30 days and 1 year post PCI
BARC types 3 or 5 bleeding at 30 days and 12 months
Time frame: 30 days and 1 year post PCI
Definite/probable stent thrombosis at 30 days and 12 months
Time frame: 30 days and 1 year post PCI
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.
Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 22 months is below that.
Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenyang Northern Hospital